Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction: A Single-center,Randomized,Open-label Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: rui yan
- Phone Number: 17746570262
- Email: yanrui4112@163.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Luhe Hospital
-
Contact:
- rui yan
- Phone Number: 17746570262
- Email: yanrui4112@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients are selected from the Cardiology Department of Beijing Luhe Hospital and have undergone direct PCI treatment for STEMI.
STEMI patients must meet the following criteria:
- Chest pain duration ≥ 30 minutes, with ST-segment elevation ≥ 0.1 mV in adjacent two leads on the electrocardiogram.
- Onset within 24 hours.
- Aged between 18 and 80 years.
- Signed informed consent form.
Exclusion Criteria:
- Hemodynamically unstable or Killip grade ≥ 2.
- Severe renal insufficiency: Glomerular filtration rate < 30 ml/min/1.73m^2.
- Active liver disease or liver dysfunction: AST or ALT levels > 3 times the upper limit of normal.
- Known allergy to any drug used in the study.
- Previous or planned use of PCSK9 inhibitors.
- Suspected stress cardiomyopathy or acute pericarditis.
- Malignant tumors requiring treatment or other severe systemic diseases.
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment arm: standard post-treatment for STEMI and Evolocumab
The intervention group will receive a preoperative subcutaneous injection of Evolocumab (420mg) and standard post-treatment for STEMI
|
Preoperative subcutaneous injection of Evolocumab (420mg),Atorvastatin 40mg per day
Other Names:
standard post-treatment for STEMI
|
|
Active Comparator: Control arm: standard post-treatment for STEMI
Standard post-treatment for STEMI
|
standard post-treatment for STEMI
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average percent change from baseline in LDL-C levels to discharge and day 30
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average percent change from baseline in total cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A and apolipoprotein B to discharge and day 30
Time Frame: 30 days
|
30 days
|
|
Average percent change from baseline in MMP-9, CSF-1, IL-18R1 to discharge and day 30
Time Frame: 30 days
|
30 days
|
|
Number of cardiovascular events to day 30
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Protease Inhibitors
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Serine Proteinase Inhibitors
- PCSK9 Inhibitors
- Evolocumab
Other Study ID Numbers
Other Study ID Numbers
- MR-11-23-035852
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.